Latest:
Common Questions From Patients About Adalimumab Biosimilars
Drs Lio, Botsoglou, and Alexrad discuss the most asked questions and common concerns patients have on adalimumab biosimilars.
© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Authors
Craig Burton
Criag Burton is the senior vice president of policy and strategic alliances at the Association for Accessible Medicines. He is also the executive director of the Biosimilars Council. In his current role, Craig is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups.
Latest:
Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition
In response to another opinion piece, Craig Burton, from the Association for Accessible Medicines, argued that the Inflation Reduction Act of 2022 could prevent biosimilar competition, and lower drug prices as a result.
Rebecca Clegg, JD
Rebecca Clegg is an associate in Axinn’s Intellectual Property group. Her practice focuses on complex intellectual property litigation and counseling, in the fields of medical devices, pharmaceuticals and biotechnology.
Latest:
Opinion: The Legal and Regulatory Year in Review
Intellectual property law attorneys from Axinn discuss regulatory and legal events in 2020 that will affect biosimilar markets in 2021.
Rabiah Dys, PharmD
Rabiah Dys, PharmD, is Senior Vice President of Clinical Program Development and Fellowship Program Director on Health Equity and Systems Thinking for CPS Solutions
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Ashley Gallagher
Ashley Gallagher is an associate editor for Pharmacy Times.
Latest:
Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance Efforts
Cencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.
Luke Halpern
Luke Halpern is an intern with
Latest:
The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs
Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.
Advertisement
Advertisement